Eylea is a medicine containing the active ingredient(s) aflibercept. On this page you will find out more about Eylea, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: aflibercept
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Eylea 4 mg/0.1 mL injection solution, 0.1 mL vial
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
EYLEA (aflibercept) is indicated in adults for the treatment of: - neovascular (wet) age-related macular degeneration (wet AMD); - visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO); - diabetic macular oedema (DME); - visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO); - visual impairment due to myopic choroidal neovascularisation (myopic CNV)
Table of characteristics
|Visual appearance||EYLEA is a sterile, clear, colourless to pale yellow, preservative-free, iso-osmotic aqueous 40 mg/mL solution for intravitreal injection.|
|Dosage Form||Injection, solution|
|Route of administration||Intravitreal-Within The Vitreous Cavity Of The Eye|
1 vial (commercial pack): Prescription Only Medicine, or Prescription Animal Remedy
1 vial (Physician's sample pack): Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Refrigerate,Do not Freeze,Protect from Light|
|Life time||24 Months|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 1 results
Eylea Intravitreal injection - myDr.com.au
Eylea Intravitreal injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 1 results
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion | Cochrane
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion
Read more on Cochrane (Australasian Centre) website